Revision as of 01:21, 31 March 2005 edit128.100.240.238 (talk) →External links← Previous edit | Revision as of 16:14, 16 August 2005 edit undoRmky87 (talk | contribs)Extended confirmed users16,215 editsNo edit summaryNext edit → | ||
Line 1: | Line 1: | ||
{| border="1" cellpadding="3" cellspacing="0" width="250px" align="right" style="border-collapse: collapse; margin: 0 0 0 0.5em" | |||
|- | |||
| bgcolor="#ffffff" align="center" colspan="2" | | |||
]<br/> | |||
''{{PAGENAME}}'' | |||
|- | |||
| align="center" colspan="2" | '']'' | |||
|- align="center" style="border-bottom: 3px solid gray" | |||
| ''']''' <br/> ? | |||
| ''']''' <br/> ? | |||
|- | |||
| bgcolor="#eeeeee" | ] | |||
| bgcolor="#ddeeff" | ? | |||
|- | |||
| bgcolor="#eeeeee" | ] | |||
| bgcolor="#ddeeff" | ? | |||
|- | |||
| bgcolor="#eeeeee" | ] | |||
| bgcolor="#ddeeff" | ? | |||
|- | |||
| bgcolor="#eeeeee" | Metabolism | |||
| bgcolor="#ddeeff" | ? | |||
|- | |||
| bgcolor="#eeeeee" | ] | |||
| bgcolor="#ddeeff" | ? | |||
|- | |||
| bgcolor="#eeeeee" | ] | |||
| bgcolor="#ddeeff" | ? | |||
|- | |||
| bgcolor="#eeeeee" | ] | |||
| bgcolor="#ddeeff" | ? | |||
|- | |||
| bgcolor="#eeeeee" | ] | |||
| bgcolor="#ddeeff" | ? | |||
|- | |||
| bgcolor="#eeeeee" | Routes of administration | |||
| bgcolor="#ddeeff" | ? | |||
|} | |||
] | ] | ||
'''Duloxetine hydrochloride''' (brand name: '''Cymbalta''') is a medically used drug that primarily targets major ] disorders (MDD) and stress urinary incontinence (SUI). Known also as LY248686, chemically (+)-(''S'')-''N''-methyl-3-(1-naphthyloxy)-2-thiophenepropanamine, it is a potent dual inhibitor of ] (5-hydroxytryptamine, 5-HT) and ] (NE) reuptake, possessing comparable affinities in binding to NE and 5-HT transport sites. Interestingly, its behavior contrasts to most other dual-reuptake inhibitors. | '''Duloxetine hydrochloride''' (brand name: '''Cymbalta''') is a medically used drug that primarily targets major ] disorders (MDD) and stress urinary incontinence (SUI). Known also as LY248686, chemically (+)-(''S'')-''N''-methyl-3-(1-naphthyloxy)-2-thiophenepropanamine, it is a potent dual inhibitor of ] (5-hydroxytryptamine, 5-HT) and ] (NE) reuptake, possessing comparable affinities in binding to NE and 5-HT transport sites. Interestingly, its behavior contrasts to most other dual-reuptake inhibitors. | ||
Line 7: | Line 46: | ||
* | * | ||
* - medlineplus.org | * - medlineplus.org | ||
] | |||
] | ] | ||
{{treatment-stub}} | {{treatment-stub}} |
Revision as of 16:14, 16 August 2005
IUPAC chemical name | |
CAS number ? |
ATC code ? |
Chemical formula | ? |
Molecular weight | ? |
Bioavailability | ? |
Metabolism | ? |
Elimination half-life | ? |
Excretion | ? |
Pregnancy category | ? |
Legal status | ? |
Routes of administration | ? |
Duloxetine hydrochloride (brand name: Cymbalta) is a medically used drug that primarily targets major depressive disorders (MDD) and stress urinary incontinence (SUI). Known also as LY248686, chemically (+)-(S)-N-methyl-3-(1-naphthyloxy)-2-thiophenepropanamine, it is a potent dual inhibitor of serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE) reuptake, possessing comparable affinities in binding to NE and 5-HT transport sites. Interestingly, its behavior contrasts to most other dual-reuptake inhibitors.
Furthermore, duloxentine lacks affinity for monoamine receptors within the central nervous system. While there is limited data available regarding the pharmacokinetic profile of duloxetine in humans, its half-life is reported to be 10 to 15 hours.
External links
- Manufacturer website
- Duloxetine - medlineplus.org
This medical treatment–related article is a stub. You can help Misplaced Pages by expanding it. |